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VISCERAL LEISHMANIASIS CAUSED BY Leishmania (Viannia) braziliensis IN A PATIENT INFECTED
WITH HUMAN IMMUNODEFICIENCY VIRUS
Eduardo Sérgio da SILVA(1,2), Raquel Silva PACHECO(3), Célia Maria Ferreira GONTIJO(1), Inácio Roberto CARVALHO(4) & Reginaldo Peçanha BRAZIL(1)
SUMMARY
The current article reports the case of a 19-month-old-girl, from the state of Minas Gerais, Brazil, with visceral leishmaniasis, by
Leishmania (Viannia) braziliensis, and Human Immunodeficiency Virus (HIV) co-infection. The child´s mother and father, aged 22
and 27 years old, respectively, were both HIV positive. The child was admitted to the General Pediatric Center, in Belo Horizonte,
presenting high fever, fatigue, weight loss and enlargement of liver and spleen. Indirect immunofluorescent test revealed a titer of
1:320 for Leishmania. Such result was confirmed by the presence of amastigotes in bone marrow aspirate samples and culture of
promastigote forms. Parasites were identified as being Leishmania (Viannia) braziliensis through PCR, using a L. braziliensis complex
primer and a generic primer, followed by hibridization. Specific leishmaniasis therapy (Glucantime antimonial) was intravenously
administered.
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INTRODUCTION
The genus Leishmania causes a variety of clinical syndromes ranging
from self-healing cutaneous lesions through metastasing mucocutaneous
forms to often lethal visceral manifestations. The severity of clinical
manifestations in immunocompetent people depends, mainly, on the
Leishmania species involved. Patients with leishmaniasis, associated with
acquired immunodeficiency syndrome (AIDS), have revealed unusual
immunopathological aspects. Most patients, suffering from Leishmania-
HIV co-infections, have shown atypical clinical profiles such as
disseminated cutaneous leishmaniasis5,14, unusual cutaneous lesions7,20,
mucosal lesions containing abundant amastigote forms4,10,23, atypical
mucocutaneous leishmaniasis caused by L. braziliensis6, cutaneous
involvement due to viscerotropic parasites21 and visceral involvement
due to dermotropic parasites12.
Leishmania has been reported to be an opportunistic parasite, in
immunosuppressed patients2 and in immunocompromised individuals such
as patients with HIV infection29, who live in endemic areas. The overlap
between VL and AIDS has increased as a consequence of the spread of the
pandemic AIDS in rural areas and that of VL to urban areas9. Consequently,
cases of Leishmania/HIV co-infection are becoming more frequent with
important clinical, diagnostic, chemotherapeutic, epidemiological and
economic implications. The major features of VL clinical picture are:
intermittent fever, spleen enlargement, pallor, fatigue, severe weight loss,
loss of appetite and pancytopenia11. The disease is fatal if not treated.
Although the incubation period of VL may vary from only 10 days to a
year, the usual incubation period ranges from 2 to 4 months9,16.
Unfortunately, VL diagnosis is difficult in such patients, since
serologic diagnosis is not sensitive enough and culture of Leishmania
parasites is both time-consuming and not always positive. Molecular
techniques for typing and diagnosing the etiological agent are very useful
for specific therapy. PACHECO et al.17 described the isolation, genotypic
and phenotypic characterization of a monoxenous trypanosomatid, found
in the bone marrow of an HIV-positive patient, presenting a visceral
leishmaniasis-like syndrome. Several authors have described PCR assays
to be used as a diagnosis method8,19,20,25,26,27. The present article describes
the case report of a VL patient, by L. braziliensis, and HIV co-infection.
METHODS
Indirect immunofluorescent assay (IFA): IFA, to detect antibodies
in serum diluted from 1:40 to 1:640, was performed according to the
manufacturer’s instructions, using a commercial kit for the diagnosis of
human leishmaniasis (FIOCRUZ/BIO-MANGUINHOS). The serological
tests, on different Leishmania species, used weakly positive titers  1:40
and strongly positive titers  1:80 as IFA cutoff values.
Parasitological test: Cell culture from bone marrow aspirate material
was performed in NNN/LIT medium, supplemented with 10% fetal calf
serum and incubated at 24-25 oC for 30 days. For direct examination of
bone marrow, the slides were stained with Giemsa and examined under
light microscopy.
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DNA extraction : A volume of 20-30 µl of blood and bone marrow
aspirates was transferred onto filter paper “FTA Cards” (Gibco BRL)
and air-dried. A small portion of the sample, on FTA paper, was removed
using a 2 mm punch and placed in a microcentrifuge tube with 200 µl of
lysis buffer (FTA processing reagent-Gibco BRL). The sample was
washed for 5 min at room temperature and centrifuged three times at
13000 g for 5 min, after which the supernatant was removed and
discarded. A volume of 200 µl TE buffer (10 mM Tris-HCl, 1 mM EDTA,
[pH 7.5]) was added to, incubated for 5 min at room temperature and the
supernatant was discarded after centrifugation, and the pellet
ressuspended in 50 µl TE. The paper-bound DNA was then ready for
analysis; the paper punch containing purified DNA was directly used
for PCR.
PCR 1: In order to amplify the conserved region of the minicircle
molecule (Kinetoplastid mitochondrial DNA; kDNA), oligonucleotides
(primer A: 5’- (G/C)(G/C)(C/G)CC(A/C)CTAT(A/T)TTACACCAACCCC;
and primer B: 5’- GGGGAGGGGCGTTCTGCGAA) were used in a hot-
start PCR procedure. Briefly, each reaction contained 100 ng of the reverse
and forward primers, 200 µM of each deoxynucleoside triphosphate
(Pharmacia, Uppsalla, Sweden), 2.5 U of Taq polymerase (Perkin-Elmer,
Norwalk, USA) in the buffer, as recommended by the manufacturer, and a
small part of the DNA paper sample. PCR amplification was carried out in
a DNA thermocycler (Perkin-Elmer) using 33 cycles at 94 °C for 30 s; at
50 °C for 30 s, and at 72 °C for 30 s, with a extension cycle for 10 min
at 72 °C.
PCR 2: Specific PCR was carried out using the B1 and B2 primers
(B1 – GGGGTTGGTGTAATATAGTGG and B2 –
CTAATTGTGCACGGGGAGG) specific for the L. braziliensis
complex8. Cycles consisted of annealing at 63 °C for 1 min, extension at
72 °C for 1 min and desnaturation at 93 °C for 30s. The programmes
were run for 35 cycles on a Perkin Elmer thermocycler (Perkin-Elmer,
USA), a final extension at 72 °C for 10 min was run.
Agarose gel electrophoresis: Each experiment included a positive
control (reference strains of Leishmania) and a negative control (rabbit
blood). Aliquots of 10 µl of the PCR reaction were analyzed by agarose
gel electrophoresis, at 100V, in the presence of ethidium bromide
(0.5 µg/ml). The expected amplification products of 120 bp (PCR 1) and
750 bp (PCR 2) were visualized under UV light.
Positive and negative controls: The reference strains L. (L.) chagasi
MHOM/BR/74/PP75 (code PP75); L. (V.) braziliensis MHOM/BR/75/
M2903 (code M2903) and L. (L.) amazonensis IFLA/BR/67/PH8 (code
PH8) were used as positive controls. The promastigotes of such strains
were transferred to the filter paper “FTA Cards” (Gibco BRL), to which
rabbit blood was added after air dried. Rabbit blood, alone on filter paper,
was used as a negative control. DNA from Leishmania reference strains
and rabbit blood were prepared according to the protocols previously
described.
Hybridization: PCR 1 products were transferred to nylon
membranes with a dot-blot apparatus and hybridized with cloned L.
braziliensis minicircles as molecular probe, radio-labeled with [-32P]
dATP, by random hexamer priming. The transferred product was
hybridized in Blotto at 65 °C, washed in 0.1X sodium saline citrate at
the same temperature, and exposed to X-ray films22.
Case report: In January 1998, a 19 month-old girl, from the small
town of Martinho Campos, in the Brazilian state of Minas Gerais, was
admitted to the General Pediatric Center, in Belo Horizonte with fever,
pneumonia, lymphodenomegalia and hepatosplenomegalia. The girl’s
mother and father, aged 22 and 27 respectively, were both HIV-positive.
The girl was delivered by caesarian section and weighed 3000 g at birth,
with a body length of 50 cm. The child was breast-fed by the mother
until 3 months old. She suffered bouts of pneumonia at 3, 5, 6, 8, 9 and
13 months of age. At 8 months, she received two blood transfusions due
to her recurrent medical profile of malnutrition, anemia, fever, pallor,
hepatomegalia and splenomegalia. At 19 months, she was diagnosed as
HIV-positive and received treatment with Zidovudine (AZT) (120 mg/
m2 every 8h), Didadosine DDI (100 mg/m2 every 12h) and intravenous
gammaglobulin. On physical examination, she was chronically ill
appearing, febrile and pale. The spleen and liver were palpable, extending
to 5 and 8 cm below the coastal margin. Laboratory data revealed platelets
(35,600/µL), hemoglobin (8.7 g/dL), normal erythrocyte, leukocytopenia.
The patient subsequently experienced respiratory failure, due to AIDS-
related pneumocytosis, and died 8 weeks later.
RESULTS
Immunological test: A positive titer was observed for Leishmania
antibodies (IFA 1:320). After 2 weeks of intermittent fever, another
positive titer for Leishmania antibodies (IFA 1:160) was noted.
Parasitological studies: The results of Leishmania IFA were
confirmed by visualization of amastigote forms, from bone marrow
aspirate, after Giemsa staining (Fig. 1) and isolation of promastigote
forms in culture. Specific therapy was initiated with intravenous
administration of antimonial Glucantime (20 mg/Kg body weight).
Fig. 1 - Smear of the bone marrow aspirate from a child with visceral leishmaniasis indicating
presence of amastigotes (2-3 µm in diameter).
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PCR for the genus Leishmania: Purified DNA from the positive
controls and the DNA, isolated from blood and bone marrow aspirate of
the patient, also yielded an amplification product (Fig. 2a). The DNA
purified from rabbit blood was negative for Leishmania, based on PCR
analysis. No contamination or inhibition was detected.
Specific PCR: The specific amplification of isolated DNA, from
blood and bone marrow, provided an amplification band similar to the
750 bp kDNA amplification band of the L. (V.) braziliensis reference
strain M2903. PCR did not amplify DNA of L. chagasi and L.
amazonensis (Fig. 3).
Hybridization: A hybridization signal was observed in the PCR
product when hybridized against a cloned minicircle of Leishmania
(Viannia) braziliensis used as probe (Fig. 2 b) thus, confirming the
specificity of the primers B1/B2 for the L. braziliensis complex.
The parasite was identified as L. (V.) braziliensis using blood and
bone marrow aspirate, the specific primer B1/B28 and PCR-hybridization
analysis.
DISCUSSION
Leishmania/HIV co-infection is considered to be an emerging disease
and a threat in several countries in accordance with WHO data. The
global experience, mainly in European countries, is marked by an
increasing number of co-infection cases in this decade, leading to
modifications concerning the epidemiological profile, presentation and
clinical outcome of visceral leishmaniasis in various countries.
Recent changes in the epidemiological profiles, identified by the
AIDS and leishmaniasis control programs, in Brazil, such as the
ruralization and pauperization of HIV infection and the simultaneous
urbanization of leishmaniasis, point to a possible expansion of people at
risk of acquiring both infections.
In Brazil, the number of cases of Leishmania/HIV co-infection is
growing in several states, including both the cutaneous and visceral
clinical presentation. However, the under-notification cases of co-
infection remains a problem with important clinical and epidemiological
implications29. DA-CRUZ et al.6 reported an atypical case of AIDS-
associated mucocutaneous leishmaniasis, due to L. braziliensis. There
are also a few reports of HIV-infected mucocutaneous leishmaniasis
patients, associated or not with cutaneous lesions4,10,15,23. In a recent case
report CHEHTER et al.3 described the involvement of the gastrointestinal
tract and dissemination forms of Leishmania, in co-infection visceral
leishmaniasis and HIV patient. In the present paper, atypical VL was
caused by L. braziliensis and the patient did not show cutaneous or
mucosal lesions. HERNANDEZ et al.13 also demonstrated L. braziliensis
as causing VL, in a patient with HIV infection. In our laboratory, we
have isolated various parasite samples from inhabitants of Martinho
Campos and characterized them as L. braziliensis; no other cases of VL
have yet been reported from the region.
In the last few years, the number of human cases of visceral and
cutaneous leishmaniasis, in the metropolitan region of Belo Horizonte
(MRBH), has increased, suggesting a rise in the transmission rates of
Leishmania species18,24. The clinical incubation period of VL typically
ranges from 6 weeks to 6 months but may vary from 10 days to 10
years1. The course of the disease is identical in children and adults. It
may suddenly begin with high fever, vomiting, diarrhea, poor appetite,
weight loss, lassitude and pallor and later produce splenomegaly,
hepatomegaly, pancytopenia, lymphadenopathy and hyperglobulinemia.
Untreated, the disease is fatal in 90% of cases within 1-3 years9.
HIV infection and Leishmania infection each induce important
similar immunological changes, worsened when there is concomitant
infection, such as a Th 1 to Th 2 response switch. However, the
consequences of the viral infection predominate1. The inhibitory effect
of HIV and Leishmania on cell proliferation and INF-gamma production
is not due to IL-10 alone, but probably operates at the level of regulation
of IFN-gamma-inducing factors, such as IL-12 and IL-1828. Patients with
HIV infection have depressed CD4+ cells, contributing to the
visceralization of Leishmania infections6,28. In the present study, however,
the patient had detectable anti-Leishmania antibodies (1:320), and
parasitological tests showed to be positive for Leishmania in bone marrow
samples. Positive PCR were obtained from the blood and bone marrow
samples. The parasite was identified as Leishmania (V.) braziliensis using
specific PCR and Southern blot analysis. The results reported here
Fig. 2 - A. PCR products obtained with primers of the genus Leishmania visualized after 2%
agarose gel electrophoresis stained with ethidium bromide. MW 50base-pair DNA ladder;
lanes 1 and 2:  bone marrow and blood from patient, lane 03: DNA of L. chagasi, lane 4:
DNA of  L. braziliensis, lane 5: DNA of  L. amazonensis and lane 6: negative control. B.
Hybridization with a cloned minicircle from L. braziliensis.
Fig. 3 - Specificity of PCR, with primers specific for L. braziliensis complex. Lane M:
molecular weight marker (MWM) X174 Hae III, lanes 1 and 2: blood and bone marrow
from patient, lane 3: L. (L.) chagasi, lane 4: L. (V.) braziliensis, lane 5: L. amazonensis, lane
6: negative control, lane 7: No DNA.
M 01 02 03 04 05 06 07
750 bp
M 1 2 3 4 5 6
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B
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reinforce the hypotesis that L. (V.) braziliensis is an opportunistic parasite
producing severe manifestations that normally do not occur in
immunocompetent individuals.
Specific diagnosis of leishmaniasis and characterization of parasites
are, therefore, important prerequisites for treatment of immuno-
compromised patients in Leishmania-endemic areas, due to their
increased risk of morbidity and mortality.
RESUMO
Leishmaniose visceral causada por Leishmania (Viannia)
braziliensis em paciente infectado com HIV
No presente artigo os autores relatam caso de uma criança de 1 ano
e 07 meses proveniente do estado de Minas Gerais com leishmaniose
visceral causada por Leishmania (Viannia) braziliensis e co-infecção
HIV. A mãe e o pai da criança de 22 e 27 anos de idade respectivamente
também HIV positivo. A criança foi internada no Centro Geral de
Pediatria em Belo Horizonte com febre alta, fadiga, perda de peso e
aumento de fígado e baço. Foi realizado teste de imunofluorescência
indireta para Leishmania e detectado título de 1:320. Este resultado foi
confirmado com o encontro de amastigotas em aspirado de medula óssea
e o crescimento de promastigotas em meios de cultura. Os parasitos
foram identificados como Leishmania (Viannia) braziliensis utilizando
PCR com primer específico para o complexo L. braziliensis, e primer
genérico seguido de hibridização. Terapia específica para leishmaniose
(antimonial de Glucantime) foi administrado por via intravenosa.
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